High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial.

IF 3.2 3区医学 Q2 RHEUMATOLOGY

Rheumatology International Pub Date : 2024-10-01 Epub Date: 2024-08-27 DOI:10.1007/s00296-024-05698-y

Kasper Yde Jensen, Per Aagaard, Charlotte Suetta, Jakob Lindberg Nielsen, Rune Dueholm Bech, Henrik Daa Schrøder, Jan Christensen, Casper Simonsen, Louise Pyndt Diederichsen

{"title":"High-intensity resistance training improves quality of life, muscle endurance and strength in patients with myositis: a randomised controlled trial.","authors":"Kasper Yde Jensen, Per Aagaard, Charlotte Suetta, Jakob Lindberg Nielsen, Rune Dueholm Bech, Henrik Daa Schrøder, Jan Christensen, Casper Simonsen, Louise Pyndt Diederichsen","doi":"10.1007/s00296-024-05698-y","DOIUrl":null,"url":null,"abstract":"<p><p>Myositis is associated with reduced quality of life, which is accompanied by significant impairments in muscle endurance and strength, altogether representing cardinal traits in patients with myositis. This randomised controlled trial aimed to investigate the effect of high-intensity resistance training on quality of life in patients with myositis. Thirty-two patients with established, stable myositis were randomised to 16 weeks of high-intensity resistance training (intervention group) or 16 weeks of usual care (control group). Primary outcome was quality of life assessed as the change in the physical component summary score (PCS) of the Short Form-36 health questionnaire from baseline to post-intervention. Secondary outcomes included functional capacity measures, such as functional index 3, and International Myositis Assessment and Clinical Studies Group (IMACS) disease activity and damage core set measures, including manual muscle testing 8 (MMT8). The primary outcome PCS showed an improvement in favour of high-intensity resistance training with a between-group difference of 5.33 (95% CI 0.61; 10.05) (p = 0.03). Additionally, functional index 3 showed a between-group difference indicating greater gains with high-intensity resistance training 11.49 (95% CI 3.37; 19.60) (p = 0.04), along with a between-group improvement in MMT8 1.30 (95% CI 0.09; 2.51) (p = 0.04). High-intensity resistance training for 16 weeks effectively improved quality of life in patients with myositis. Clinical measures of muscle endurance and muscle strength were also found to improve with high-intensity resistance training, while patients stayed in disease remission. Consequently, progressively adjusted high-intensity resistance training is feasible and causes no aggravation of the disease, while benefitting patients with myositis.Clinical trial registration: Clinicaltrials.gov ID: NCT04486261- https://clinicaltrials.gov/study/NCT04486261 .</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":" ","pages":"1909-1921"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392978/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-024-05698-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Myositis is associated with reduced quality of life, which is accompanied by significant impairments in muscle endurance and strength, altogether representing cardinal traits in patients with myositis. This randomised controlled trial aimed to investigate the effect of high-intensity resistance training on quality of life in patients with myositis. Thirty-two patients with established, stable myositis were randomised to 16 weeks of high-intensity resistance training (intervention group) or 16 weeks of usual care (control group). Primary outcome was quality of life assessed as the change in the physical component summary score (PCS) of the Short Form-36 health questionnaire from baseline to post-intervention. Secondary outcomes included functional capacity measures, such as functional index 3, and International Myositis Assessment and Clinical Studies Group (IMACS) disease activity and damage core set measures, including manual muscle testing 8 (MMT8). The primary outcome PCS showed an improvement in favour of high-intensity resistance training with a between-group difference of 5.33 (95% CI 0.61; 10.05) (p = 0.03). Additionally, functional index 3 showed a between-group difference indicating greater gains with high-intensity resistance training 11.49 (95% CI 3.37; 19.60) (p = 0.04), along with a between-group improvement in MMT8 1.30 (95% CI 0.09; 2.51) (p = 0.04). High-intensity resistance training for 16 weeks effectively improved quality of life in patients with myositis. Clinical measures of muscle endurance and muscle strength were also found to improve with high-intensity resistance training, while patients stayed in disease remission. Consequently, progressively adjusted high-intensity resistance training is feasible and causes no aggravation of the disease, while benefitting patients with myositis.Clinical trial registration: Clinicaltrials.gov ID: NCT04486261- https://clinicaltrials.gov/study/NCT04486261 .

Abstract Image

查看原文本刊更多论文

高强度阻力训练可提高肌炎患者的生活质量、肌肉耐力和力量：随机对照试验。

肌炎与生活质量下降有关，与此同时，肌炎患者的肌肉耐力和力量也明显受损，而这两点正是肌炎患者的主要特征。这项随机对照试验旨在研究高强度阻力训练对肌炎患者生活质量的影响。32名已确诊、病情稳定的肌炎患者被随机分为16周高强度阻力训练组（干预组）或16周常规护理组（对照组）。主要结果是生活质量，即短表-36健康问卷中身体部分总分（PCS）从基线到干预后的变化。次要结果包括功能指数3等功能能力测量，以及国际肌炎评估和临床研究小组（IMACS）疾病活动和损伤核心组测量，包括徒手肌肉测试8（MMT8）。主要结果PCS显示，高强度阻力训练有利于病情改善，组间差异为5.33（95% CI 0.61; 10.05）（P = 0.03）。此外，功能指数 3 显示出了组间差异，表明高强度阻力训练的收益更大，为 11.49 (95% CI 3.37; 19.60) (p = 0.04)，MMT8 的组间差异为 1.30 (95% CI 0.09; 2.51) (p = 0.04)。为期16周的高强度阻力训练能有效改善肌炎患者的生活质量。研究还发现，高强度抗阻力训练还能改善肌耐力和肌力的临床指标，而患者的病情仍处于缓解期。因此，逐步调整的高强度阻力训练是可行的，而且不会加重病情，同时还能使肌炎患者受益：临床试验注册：Clinicaltrials.gov ID：NCT04486261- https://clinicaltrials.gov/study/NCT04486261 .

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology International 医学-风湿病学

CiteScore

7.30

自引率

5.00%

发文量

191

审稿时长

16. months

期刊介绍： RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.